IKT today
$1.56-$0.07 (-4.29%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourLeaning Bullish
15 minDescending Triangle
5 minStrong Bullish
Daily trend turns down below $1.12
Key levels
Resistance$1.70
Resistance$1.57
Support$1.43
Latest news & SEC filings
AnalystHC Wainwright reiterates Buy on Inhibikase Therapeutics with $8 target
EarningsInhibikase Therapeutics Posts Q3 2026 Financials
SEC FilingInhibikase Therapeutics, Inc. filed a report on a major company event (Form 8-K)
EarningsInhibikase Therapeutics posts smaller quarterly loss than expected
All IKT news →About Inhibikase Therapeutics
Inhibikase Therapeutics is a drug developer focused on therapies for heart and lung conditions. Its main candidate, IKT-001, is an oral medicine derived from imatinib and is being tested for pulmonary arterial hypertension, a rare vascular disease of the lungs. The company runs a late-stage trial of IKT-001 in patients with this condition. It is based in the United States and uses outside contractors to make its clinical supplies.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Inhibikase Therapeutics, Inc. (IKT)
What Is the Price Target for IKT?
SEPT Low Target
$1.50
SEPT Mid Target
$3.25
SEPT High Target
$5.00
Analyst Consensus
$3.25
Is IKT a Buy or Sell Right Now?
Thesis
- •Revenue growing 111.0% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IKT.
Start Free Trial →Is IKT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$3.00
27
Moat Score
NONE
2/9
Piotroski Score
9.8
Altman Z-Score
What Is Smart Money Doing with IKT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IKT Growth Story
Revenue YoY
111.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
57.76%
FCF Growth YoY
-45.2%
Revenue Trend
ACCELERATING
Dark Pool Trades for IKT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IKT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:58:45 | $1.63 | 1,617 | $$3K | MIDPOINT |
| 20:58:45 | $1.63 | 1,158 | $$2K | SELL |
| 20:43:27 | $1.62 | 1,200 | $$2K | SELL |
| 19:36:50 | $1.63 | 2,800 | $$5K | SELL |
| 19:05:36 | $1.63 | 2,800 | $$5K | MIDPOINT |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Inhibikase Therapeutics, Inc. (IKT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IKT — frequently asked questions
What is IKT stock price today?
Inhibikase Therapeutics, Inc. (IKT) is at $1.56, down 4.29% (-$0.07) at the Nov 12, 2026 close.
Why is IKT stock moving today?
Latest IKT news — Nov 12, 2026: HC Wainwright reiterates Buy on Inhibikase Therapeutics with $8 target · Nov 11, 2026: Inhibikase Therapeutics Posts Q3 2026 Financials
What is the IKT price target?
The average analyst price target for IKT is $3.25, ranging from $2 to $5, based on 2 analysts. Latest: Chardan Capital initiates on Oct 13, 2026.
What do analysts rate IKT?
Analyst ratings for IKT: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did IKT beat earnings?
IKT last reported on Aug 11, 2026: EPS -$0.11 vs -$0.11 expected — a miss of 2.3%.
Does IKT pay a dividend?
IKT does not currently pay a dividend.
What are IKT support and resistance levels?
Support: $1.43. Resistance: $1.57, $1.70, $1.87.
What are insiders doing with IKT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on IKT?
Nov 12, 2026: HC Wainwright reiterates Buy on Inhibikase Therapeutics with $8 target · Nov 11, 2026: Inhibikase Therapeutics Posts Q3 2026 Financials · Nov 10, 2026: Inhibikase Therapeutics, Inc. filed a report on a major company event (Form 8-K)